Co-Authors
This is a "connection" page, showing publications co-authored by Dina Visca and Simon Tiberi.
Connection Strength
0.975
-
Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology. 2021 Mar-Apr; 27(2):151-165.
Score: 0.231
-
Tuberculosis in the time of COVID-19: quality of life and digital innovation. Eur Respir J. 2020 08; 56(2).
Score: 0.224
-
Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. J Bras Pneumol. 2019 Apr 25; 45(2):e20180324.
Score: 0.205
-
Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology. 2021 May-Jun; 27(3):248-256.
Score: 0.058
-
Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J. 2020 10; 56(4).
Score: 0.057
-
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020 07; 56(1).
Score: 0.056
-
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. Eur Respir J. 2018 07; 52(1).
Score: 0.048
-
Tuberculosis elimination: where are we now? Eur Respir Rev. 2018 Jun 30; 27(148).
Score: 0.048
-
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis. J Bras Pneumol. 2018 Apr; 44(2):153-160.
Score: 0.048